MedPath

Telemedicine Home-based Management in Patients With CHF and Type 2 Diabetes

Not Applicable
Completed
Conditions
Chronic Heart Failure
Diabetes Mellitus
Interventions
Other: Teleassistance
Other: Quality of life
Other: Biochemistry evaluation
Other: Teleconsultation
Other: Telerehabilitation
Other: Telemonitoring
Other: mHealth
Other: telepsycology
Other: Clinical evaluation
Other: State of health of the patient
Registration Number
NCT05633784
Lead Sponsor
Istituti Clinici Scientifici Maugeri SpA
Brief Summary

The progressive ageing of the population of industrialized countries is accompanied by a dramatic increase in the prevalence of chronic multi-pathologies. In the general population, HF is associated with a higher prevalence of T2DM compared with patients without HF and with marked regional differences observed in Europe and the rest of the world. In clinical trials of chronic HF patients, the prevalence of T2DM is approximately 30% in patients with reduced or preserved ejection fraction and rises to as much as 45% in hospitalized patient registries. A complex drug regimen is often associated with low adherence in patients with HF and T2DM and poor adherence is associated with adverse clinical events. Similarly, adherence to recommendations regarding lifestyle changes, such as increasing physical activity, is often limited despite these changes' favourable effects on the patient. Therefore, interventions are needed to improve all these factors and optimize adherence. The inclusion of telemedicine (telenursing, telerehabilitation, mHealth) focused on health and correct behaviour can create opportunities to implement customized and scalable solutions in populations at risk. The project will aim to evaluate for patients with chronic diseases with a complex phenotype (heart failure and type II diabetes mellitus) the effectiveness of a remote surveillance program with particular attention to lifestyle changes.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
163
Inclusion Criteria
  • Inform consent
  • Age ≥ 18 years
  • Documented diagnosis of heart failure, NYHA class II-III (reduced or preserved Ejection fraction without hospitalization in the last 3 months
  • Diagnosis of Diabetes Mellitus Type II in pharmacological treatment from at least one month
  • Ability to walk without assistive devices
  • Consent to using a device (independently or with the support of a caregiver) for recording the single electrocardiographic trace at home
  • Consent to using the App
Exclusion Criteria
  • Subjects with poor collaboration
  • No possibility of using mobile technology
  • Life expectancy of fewer than 6 months
  • Medical issues that preclude participation in the program

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intervention groupTeleassistanceAt the beginning and at the end of the 6-month study period, patients of the Intervention group will perform outpatient cardiological visits. During the 6-month they will be followed through a home remote teleassistance program, designed to provide multidisciplinary support.
Intervention groupmHealthAt the beginning and at the end of the 6-month study period, patients of the Intervention group will perform outpatient cardiological visits. During the 6-month they will be followed through a home remote teleassistance program, designed to provide multidisciplinary support.
Intervention groupState of health of the patientAt the beginning and at the end of the 6-month study period, patients of the Intervention group will perform outpatient cardiological visits. During the 6-month they will be followed through a home remote teleassistance program, designed to provide multidisciplinary support.
Control groupBiochemistry evaluationAt the beginning and at the end of the 6-month study period, patients of the Control group will perform outpatient cardiological visits. During the 6-month at home, patients will be followed in the usual care model by GP.
Intervention groupTeleconsultationAt the beginning and at the end of the 6-month study period, patients of the Intervention group will perform outpatient cardiological visits. During the 6-month they will be followed through a home remote teleassistance program, designed to provide multidisciplinary support.
Intervention grouptelepsycologyAt the beginning and at the end of the 6-month study period, patients of the Intervention group will perform outpatient cardiological visits. During the 6-month they will be followed through a home remote teleassistance program, designed to provide multidisciplinary support.
Control groupState of health of the patientAt the beginning and at the end of the 6-month study period, patients of the Control group will perform outpatient cardiological visits. During the 6-month at home, patients will be followed in the usual care model by GP.
Intervention groupTelerehabilitationAt the beginning and at the end of the 6-month study period, patients of the Intervention group will perform outpatient cardiological visits. During the 6-month they will be followed through a home remote teleassistance program, designed to provide multidisciplinary support.
Intervention groupBiochemistry evaluationAt the beginning and at the end of the 6-month study period, patients of the Intervention group will perform outpatient cardiological visits. During the 6-month they will be followed through a home remote teleassistance program, designed to provide multidisciplinary support.
Intervention groupClinical evaluationAt the beginning and at the end of the 6-month study period, patients of the Intervention group will perform outpatient cardiological visits. During the 6-month they will be followed through a home remote teleassistance program, designed to provide multidisciplinary support.
Control groupQuality of lifeAt the beginning and at the end of the 6-month study period, patients of the Control group will perform outpatient cardiological visits. During the 6-month at home, patients will be followed in the usual care model by GP.
Intervention groupTelemonitoringAt the beginning and at the end of the 6-month study period, patients of the Intervention group will perform outpatient cardiological visits. During the 6-month they will be followed through a home remote teleassistance program, designed to provide multidisciplinary support.
Intervention groupQuality of lifeAt the beginning and at the end of the 6-month study period, patients of the Intervention group will perform outpatient cardiological visits. During the 6-month they will be followed through a home remote teleassistance program, designed to provide multidisciplinary support.
Control groupClinical evaluationAt the beginning and at the end of the 6-month study period, patients of the Control group will perform outpatient cardiological visits. During the 6-month at home, patients will be followed in the usual care model by GP.
Primary Outcome Measures
NameTimeMethod
Change in tolerance capacityBaseline and 6 months

The change from baseline in tolerance capacity will be measured by walking test performance (meters walked).

Secondary Outcome Measures
NameTimeMethod
Change of hospitalizations6 months

Change of hospitalizations for cardiovascular problems, diabetes and all-causes

Number of StepsBaseline and 6 months

The difference in the weekly mean in the number of steps from baseline over the 6 months of follow-up.

Change in quality of life related to DiabetesBaseline and 6 months

Change in quality of life measured by Diabetes quality of life (DQoL) questionnaire

Change in quality of lifeBaseline and 6 months

Change in quality of life measured by 12-item Short Form Survey (SF-12) questionnaire

Assessment of physical activity.Baseline and 6 months

Change in physical activity profile by Physical Activity Scale for the Elderly (PASE).

The total PASE score is computed by multiplying the amount of time spent on each activity (hours/week) or participation (yes/no) in an activity by the empirically derived item weights and summing overall activities.

Change in quality of life related to heart failureBaseline and 6 months

Change in quality of life measured by Minnesota Living with Heart Failure (MLHFQ) questionnaire

HbA1c dosageBaseline and 6 months

Change of the disease status

Trial Locations

Locations (3)

Azienda Ospedaliera Bolognini di Seriate Bergamo

🇮🇹

Seriate, Bergamo, Italy

Istituti Clinici Scientifici Maugeri

🇮🇹

Lumezzane, Brescia, Italy

Papa Giovanni XXIII Hospital

🇮🇹

Bergamo, Italy

© Copyright 2025. All Rights Reserved by MedPath